Aspen Pharmacare Holdings Limited is a multinational pharmaceutical company headquartered in Durban, South Africa. Founded in 1997 by Stephen Saad and Gus Attridge, Aspen has grown from a regional generic drug producer into a global specialist in branded and generic medicines. The company is publicly traded on the Johannesburg Stock Exchange and its American depositary receipts trade over‐the‐counter under the symbol APNHY.
Aspen’s core business encompasses the development, manufacture and distribution of a broad portfolio of injectable and oral pharmaceutical products. Key therapeutic areas include oncology, anesthesia, thrombosis, hormone replacement therapy and antibiotics. The company operates multiple manufacturing sites that adhere to strict international standards, supporting both its own brands and third-party licensing agreements.
With a presence in more than 150 countries, Aspen serves markets across Africa, Europe, Australasia and Latin America. It combines global reach with focused local marketing and distribution networks, enabling the company to address diverse healthcare needs in both emerging and developed economies. Strategic partnerships and in-licensing deals further extend Aspen’s product offerings and geographic footprint.
Leadership at Aspen remains anchored by co-founder and Chief Executive Officer Stephen Saad, who has guided the company’s expansion since inception. Gus Attridge, co-founder and executive deputy chairman, contributes extensive industry experience to the company’s governance. Together, they oversee an executive team dedicated to sustainable growth, innovation and compliance with international regulatory requirements.
AI Generated. May Contain Errors.
